BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
BIO 368.42 +10.23(2.86%)
Will BIO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIO
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What to Expect From These 3 MedTech Stocks This Earnings Season
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?
Other News for BIO
Bio-Rad Laboratories Inc (BIO) Shares Up 3.17% on Nov 1
Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)
Bio-Rad Labs misses Q3 estimates for profit, revenue
Bio-Rad Laboratories Inc (BIO) Trading 7.76% Higher on Oct 31
Bio-Rad price target raised to $469 from $446 at RBC Capital